FMP

FMP

Enter

VNDA - Vanda Pharmaceu...

photo-url-https://images.financialmodelingprep.com/symbol/VNDA.png

Vanda Pharmaceuticals Inc.

VNDA

NASDAQ

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

4.13 USD

0.05 (1.21%)

Historical Prices

From:

To:

3.953.963.994.024.054.084.114.1409:33 AM10:01 AM10:21 AM10:46 AM11:03 AM11:21 AM11:40 AM11:55 AM12:18 PM12:44 PM12:59 PM01:17 PM01:36 PM01:57 PM02:19 PM02:43 PM03:04 PM03:17 PM03:37 PM03:50 PM

About

ceo

Dr. Mihael H. Polymeropoulos M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule ...

CIK

0001347178

ISIN

US9216591084

CUSIP

921659108

Address

2200 Pennsylvania Avenue NW

Phone

202 734 3400

Country

US

Employee

368

IPO Date

Apr 12, 2006

Financial Statement

-10M010M20M30M40M50M60M2023 Q42024 Q12024 Q22024 Q32024 Q4RevenueNet Income

Earnings

-0.25-0.2-0.15-0.1-0.0500.052023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

VNDA Financial Summary

CIK

0001347178

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

921659108

ISIN

US9216591084

Country

US

Price

4.13

Beta

0.72

Volume Avg.

694.17k

Market Cap

240.85M

Shares

-

52-Week

3.85-6.75

DCF

9.36

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-12.52

P/B

-

Website

https://www.vandapharma.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest VNDA News

PRNewsWire

Jul 26, 2024

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financ...

Conference Call and Webcast to Follow WASHINGTON , July 26, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2024 on Wednesday, July 31, 2024, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, July 31, 2024, during which management will discuss the second quarter 2024 financial results and other corporate activities.

Reuters

Jun 26, 2024

Future Pak withdraws offer to buy Vanda Pharmaceuticals

Contract manufacturer Future Pak said on Wednesday it has withdrawn its offer to acquire Vanda Pharmaceuticals , citing non-engagement from the U.S. drugmaker.

Reuters

Jun 19, 2024

Vanda rejects Future Pak and Cycle Pharma's takeover offers

Vanda Pharmaceuticals said on Wednesday that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers undervalue the U.S. drugmaker.

Seeking Alpha

Jun 17, 2024

Vanda Pharmaceuticals: Undervalued With Promising Pipeline A...

Vanda Pharmaceuticals' portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA's upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA's undervaluation and strategic value.

Reuters

Jun 13, 2024

Future Pak raises cash portion of buyout offer for Vanda

Contract manufacturer Future Pak said on Thursday it has raised the cash portion of its buyout offer as part of a final attempt to acquire Vanda Pharmaceuticals.

Zacks Investment Research

Jun 7, 2024

Vanda (VNDA) Surges 24.2%: Is This an Indication of Further ...

Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CNBC International TV

May 31, 2024

Vanda Insights: Aramco share sale is not surprising

Vandana Hari, founder of Vanda Insights, says it'll be a "test of investor appetite."

PRNewsWire

May 30, 2024

Vanda Pharmaceuticals Announces Participation in the Jefferi...

WASHINGTON , May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New York City on Thursday, June 6, 2024. A corporate presentation is scheduled for 2:00 p.m.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep